PMV Pharmaceuticals (PMVP) halts unused $114M stock program

Rhea-AI Filing Summary

PMV Pharmaceuticals, Inc. (PMVP) is updating its previously filed at-the-market equity program. The company had registered the offer and sale of its common stock under an Open Market Sale Agreement with Jefferies LLC, permitting issuances of shares with an aggregate offering price of up to $113,792,846.40 from time to time. This supplement terminates the company’s continuous offering under that ATM prospectus supplement, and PMV Pharmaceuticals states that no shares of common stock were sold under the program. The termination does not otherwise change the underlying sales agreement or the parties’ rights and obligations under it.

Key Figures

Aggregate offering price capacity: $113,792,846.40 Par value per share: $0.00001 per share Supplement date: August 31, 2026

3 metrics

Aggregate offering price capacity $113,792,846.40 Maximum aggregate offering price of common stock previously registered under the ATM prospectus supplement

Par value per share $0.00001 per share Par value of PMV Pharmaceuticals’ common stock eligible to be sold under the ATM

Supplement date August 31, 2026 Date of Supplement No. 1 terminating the continuous offering under the ATM prospectus supplement

Key Terms

at the market offering, Open Market Sale Agreement, Rule 415(a)(4), prospectus supplement

4 terms

at the market offering financial

"deemed an “at the market offering” as defined in Rule 415(a)(4)"

An at-the-market offering is a way a company raises cash by selling newly issued shares directly into the open market at prevailing prices, rather than all at once in a single deal. Think of it like turning a faucet on to drip shares into trading at current prices when needed; it gives the company flexibility to raise funds over time but can dilute existing shareholders and potentially affect the stock price, which investors should monitor.

Open Market Sale Agreement financial

"under the terms of an Open Market Sale , or the sales agreement"

A contract that lets a shareholder or issuer authorize a broker to sell stock into the public market over time rather than to one specific buyer. Think of it like hiring a salesperson to quietly sell items from your garage in small batches so you don’t crash the price; for investors it matters because it increases supply and liquidity, can put downward pressure on the share price, and signals an upcoming flow of shares into the market.

Rule 415(a)(4) regulatory

"as defined in Rule 415(a)(4) promulgated under the Securities Act"

Rule 415(a)(4) is a U.S. Securities and Exchange Commission rule that lets a company add more securities to an already effective shelf registration, so those additional shares or bonds can be sold later without filing a completely new registration. For investors it matters because it gives the issuer the flexibility to raise cash quickly—like having an open credit line—while creating the possibility of dilution or changes in supply that can affect share price.

prospectus supplement regulatory

"the prospectus supplement, dated November 27, 2024 (the “ATM Prospectus Supplement”)"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

Offering Details

ATM

Offering

Offering Type ATM

FAQ

What is PMVP changing with this 424B3 supplement to its ATM program?

PMV Pharmaceuticals is terminating its continuous offering under a prior at-the-market prospectus supplement. The company had the ability to sell common stock under an Open Market Sale Agreement with Jefferies but is ending that specific ATM prospectus supplement through this filing.

How large was PMVP’s ATM facility described in this supplement?

The at-the-market program previously allowed PMV Pharmaceuticals to offer and sell common stock having an aggregate offering price of up to $113,792,846.40 from time to time through Jefferies LLC as sales agent.

Did PMVP sell any shares under the terminated ATM prospectus supplement?

No. PMV Pharmaceuticals states that it did not sell any shares of its common stock under the prior ATM prospectus supplement before terminating the continuous offering with this supplement.

Does this supplement affect PMVP’s Open Market Sale Agreement with Jefferies?

The company states that terminating the continuous offering under the ATM prospectus supplement does not impact the Sales Agreement itself or the related rights and obligations of PMV Pharmaceuticals and Jefferies LLC.

What type of offering structure did PMVP’s ATM program use?

The program involved sales of PMV Pharmaceuticals’ common stock through Jefferies LLC acting as sales agent by methods that are deemed an “at the market offering” under Rule 415(a)(4) of the Securities Act of 1933.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/31/2026 - 05:04 PM Accepted by SEC EDGAR 08/31/2026 - 05:01 PM Learn about SEC filing dates

Filed Pursuant to Rule 424(b)(3)
Registration No. 333-283349

SUPPLEMENT NO. 1 TO PROSPECTUS SUPPLEMENT DATED NOVEMBER 27, 2024

(To Prospectus dated November 27, 2024)

This Supplement No. 1 to Prospectus Supplement (this “Supplement No. 1”) amends and supplements the information in the prospectus, dated November 27, 2024, (the “Prospectus”), and the prospectus supplement, dated November 27, 2024 (the “ATM Prospectus Supplement”), of PMV Pharmaceuticals, Inc. This Supplement No. 1 should be read in conjunction with and is qualified in its entirety by reference to the ATM Prospectus Supplement, except to the extent that the information herein amends or supersedes the information contained therein. Throughout this Supplement No. 1, the terms “we,” “us,” “our” and the “Company” refer to PMV Pharmaceuticals, Inc., a Delaware corporation.

We filed the ATM Prospectus Supplement on November 27, 2024 to register the offer and sale of shares of our common stock from time to time under the terms of an Open Market Sale Agreement^SM, or the sales agreement, dated October 4, 2021, with Jefferies LLC, or Jefferies. In accordance with the terms of the sales agreement, under the ATM Prospectus Supplement, we could offer and sell shares of our common stock, par value $0.00001 per share, having an aggregate offering price of up to $113,792,846.40 from time to time through Jefferies, acting as our sales agent by any method permitted that is deemed an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended.

The purpose of this Supplement No. 1 is to terminate our continuous offering under the ATM Prospectus Supplement. We did not sell any shares of our Common Stock under the ATM Prospectus Supplement. The termination of our continuous offering under the ATM Prospectus Supplement does not otherwise impact the Sales Agreement and our rights and obligations thereunder.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement. Any representation to the contrary is a criminal offense.

The date of this Supplement No. 1 is August 31, 2026.